Minerva Neuro provides update on clinical development of three candidates

|About: Minerva Neurosciences,... (NERV)|By:, SA News Editor

Minerva Neurosciences (NASDAQ:NERV) updates investors on the clinical development of three of its product candidates:

MIN-101: Patient enrollment target of 234 in its Phase 2a trial in schizophrenia will be hit later this month. Top-line results for the core 12-week treatment evaluation period should be available in Q2 2016. Patients who respond positively to treatment will have the opportunity to enter into a six-month active treatment extension period.

MIN-202: Patient enrollment completed in two studies, insomnia disorder and adjunctive treatment of major depressive disorder (MDD). The Phase 2a insomnia trial is assessing MIN-202 in 26 patients without psychiatric co-morbidity. The primary endpoint is sleep efficiency as measure by polysomnography. The Phase 2b MDD study is evaluating MIN-202 in 48 patients who are receiving either diphenhydramine or placebo. The primary endpoint is safety. Secondary endpoints include assessments of depressive symptoms, cognition and sleep.

MIN-117: Patient recruitment ongoing in a Phase 2a study in MDD. Target enrollment is 80. The study is comparing two doses of MIN-117 to paroxetine and placebo. The primary endpoint is the efficacy of MIN-117 in reducing depressive symptoms versus placebo. Top-line data are expected in H1 2016.

Subscribe for full text news in your inbox